Biocon has reported results for the fourth quarter and year ended March 31, 2013
The company has reported a fall of 38.54% in its net profit at Rs 38.29 crore for the quarter ended March 31, 2013 as compared to Rs 62.30 crore for the same quarter in the previous year. Total income from operation of the company has increased by 9.98% at Rs 475.79 crore for quarter under review as compared to Rs 432.60 crore for the quarter ended March 31, 2012.
On the consolidated basis, the company has reported over 2.5 fold jump in its net profit at Rs 248.61 crore for the quarter ended March 31, 2013 as compared to Rs 97.80 crore for the same quarter in the previous year. Total income from operation of the company has increased by 4.41% at Rs 637.08 crore for quarter under review as compared to Rs 610.20 crore for the quarter ended March 31, 2012.
For the year ended March 31, 2013, the company has posted a rise of 7.91% in its net profit at Rs 275.70 crore as compared to Rs 255.50 crore for the same period in the previous year. Total income from operation has increased by 24.56% at Rs 1938.00 crore for year under review as compared to Rs 1555.85 crore for the period ended March 31, 2012.
For the year ended March 31, 2013, on the consolidated basis, the company has posted a rise of 50.36% in its net profit at Rs 508.82 crore as compared to Rs 338.40 crore for the same period in the previous year. Total income from operation increased by 19.11% at Rs 2485.30 crore for year under review as compared to Rs 2086.52 crore for the period ended March 31, 2012.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1670.40 |
| Dr. Reddys Lab | 1236.50 |
| Cipla | 1234.30 |
| Zydus Lifesciences | 942.40 |
| Lupin | 2332.80 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: